Inhibition of 6-formylindolo[3,2-b]carbazole metabolism sensitizes keratinocytes to UVA-induced apoptosis: Implications for vemurafenib-induced phototoxicity

Katharina M. Rolfs a, Natalie C. Sondermann a, Christian Vogeley a, Julien Dairou b, Viola Gilardino a, Ragnhild Wirth a, Stephan Meller c, Bernhard Homey c, Jean Krutmann a, d, Dieter Lang e, Motoki Nakamura a, f, Thomas Haarmann-Stemmann a, *

a IUF – Leibniz Research Institute for Environmental Medicine, 40225, Düsseldorf, Germany
b Department of Dermatology, Medical Faculty, Heinrich-Heine-University, 40225, Düsseldorf, Germany
c Medical Faculty, Heinrich-Heine-University, 40225, Düsseldorf, Germany
d Bayer AG, Drug Metabolism and Pharmacokinetics, Research Center, 42096, Wuppertal, Germany
e Leibniz-Research Institute for Environmental Medicine, 40225, Düsseldorf, Germany
f Medical Faculty, Heinrich-Heine-University, 40225, Düsseldorf, Germany

department of Environmental and Geriatric Dermatology, Graduate School of Medical Sciences, Nagoya City University, Nagoya, 467-8601, Japan

ARTICLE INFO

Keywords:
Adverse drug reactions
Apoptosis
 Aryl hydrocarbon receptor
 Cytochrome P450
 Phototoxicity
 Ultraviolet radiation

ABSTRACT

Ultraviolet (UV) B irradiation of keratinocytes results in the formation of the tryptophan photoproduction 6-formylindolo[3,2-b]carbazole (FICZ) which is a high-affinity ligand for the aryl hydrocarbon receptor (AHR). The resulting activation of AHR signaling induces the expression of cytochrome P450 (CYP) 1A1 which subsequently metabolizes FICZ. Importantly, FICZ is also a nanomolar photosensitizer for UVA radiation. Here, we assess whether a manipulation of the AHR-CYP1A1 axis in human epidermal keratinocytes affects FICZ/UVA-induced phototoxic effects and whether this interaction might be mechanistically relevant for the phototoxicity of the BRAF inhibitor vemurafenib. Treatment of keratinocytes with an AHR agonist enhanced the CYP1A1-catalyzed metabolism of FICZ and thus prevented UVA photosensitization, whereas an inhibition of either AHR signaling or CYP1A1 enzyme activity resulted in an accumulation of FICZ and a sensitization to UVA-induced oxidative stress and apoptosis. Exposure of keratinocytes to vemurafenib resulted in the same outcome. Specifically, CYP phenotyping revealed that vemurafenib is primarily metabolized by CYP1A1 and to a lesser degree by CYP2J2 and CYP3A4. Hence, vemurafenib sensitized keratinocytes to UVA-induced apoptosis by interfering with the CYP1A1-mediated oxidative metabolism of FICZ. In contrast to this pro-apoptotic effect, a treatment of UVB-damaged keratinocytes with vemurafenib suppressed apoptosis, a process which might contribute to the skin carcinogenicity of the drug. Our results provide insight into the mechanisms responsible for the photosensitizing properties of vemurafenib and deliver novel information about its metabolism which might be relevant regarding potential drug-drug interactions. The data emphasize that the AHR-CYP1A1 axis contributes to the pathogenesis of cutaneous adverse drug reactions.

1. Introduction

Exposure of the skin to ultraviolet (UV) radiation causes a variety of acute (e.g. sunburn) and chronic (e.g. aging, cancer) adverse health effects [1–3]. The majority of these effects is triggered by UV-induced DNA damage and associated signaling responses. Whereas UVA radiation (315–400 nm) penetrates deep into the skin and even reaches dermal fibroblasts, UVB rays (280–315 nm) are nearly completely absorbed by macromolecular structures, in particular the DNA, of epidermal cells [1–3]. UVB irradiation leads to the formation of mutagenic cyclobutane pyrimidine dimers (CPDs) and pyrimidine-pyrimidone (6–4) photoproducts [4], whereas UVA rays are poorly absorbed by DNA and exert their harmful effects, i.e. oxidative damage of cellular macromolecules, mainly through an excitation of endogenous photosensitizers, such as protoporphyrin IX and riboflavin, and the resulting formation of reactive oxygen species (ROS) [5]. In
addition, various oral drugs, including antibiotics, statins and non-steroidal anti-inflammatory drugs, have been identified as potent photosensitizers. Accordingly, cutaneous photocarcinogenesis is a common side effect of drug treatment [6-7]. A prominent example for a photosensitizing drug is vemurafenib (PLX 4032, Zelboraf®), a protein kinase inhibitor approved for the treatment of advanced melanoma and Erdheim-Chester disease with BRAF V600 gain-of-function mutations [8-10]. An enhanced sensitivity to UVA radiation affects 35%-63% of the melanoma patients and is one of the most common side effects of vemurafenib treatment [11,12].

Besides DNA, tryptophan is a potent chromophore for UVB radiation. In keratinocytes, absorption of UVB rays by cytosolic tryptophan leads to the formation of 6-formylindolo[3,2-b]carbazole (FICZ) and other tryptophan photoproducts [13-16]. FICZ is a high-affinity ligand of the aryl hydrocarbon receptor (AHR), a key regulator in xenobiotic metabolism and immunity [17-19]. Upon its activation, AHR shuttles into the nucleus and induces the expression of target genes, for instance encoding cytochrome P450 (CYP) 1A1 and CYP1B1. Importantly, CYP1A1 rapidly monohydroxylates FICZ to enable its detoxification by sulfotransferases and other conjugating enzymes [20,21], thereby ensuring a transient AHR activation by the tryptophan photoproduct [22]. In concert with other signaling pathways, AHR orchestrates UVB stress responses in epidermal cells [22,23].

However, FICZ does not only serve as AHR agonist but is also a potent photosensitizer for UVA radiation [24]. In fact, the Wondrak laboratory has shown that UVA irradiation of FICZ-treated keratinocytes results in ROS generation and associated DNA damage [24]. In a follow-up work, the group proposed to harness the UVA-sensitizing properties of FICZ for the photodynamic elimination of skin cancer [25]. Other investigators, however, suggested that FICZ may contribute to UV-induced skin carcinogenesis by photochemically damaging DNA repair enzymes [26].

Here, we investigated whether a modulation of AHR signaling and/or CYP1A1 enzyme activity stabilizes intracellular FICZ levels and sensitizes keratinocytes to UVA-induced apoptosis. In addition, we assessed whether vemurafenib enhances UVA-induced keratinocyte apoptosis by interfering with the CYP1A1-catalyzed metabolism of FICZ. We performed enzyme activity assays and a detailed CYP phenotyping to identify CYP isoforms involved in the metabolism of vemurafenib. Finally, we analyzed the impact of vemurafenib on the apoptotic clearance of UVB-irradiated keratinocytes harboring mutagenic DNA photoproducts.

2. Results

2.1. FICZ sensitizes human keratinocytes to UVA-induced apoptosis

Treatment of HaCat keratinocytes with FICZ for 30 min and a subsequent exposure to a low dose of 5 J/cm² UVA radiation resulted in a dose-dependent induction of caspase-3 activity (Fig. 1A). While an exposure to FICZ or UVA radiation alone had no effect, we observed a slight increase of caspase-3 activity in cells pretreated with 50 nM FICZ. A pretreatment with 100 nM FICZ resulted in a nearly 10-fold induction of caspase-3 activity upon UVA irradiation, whereas a FICZ pretreatment for 4 h did not significantly enhance UVA-induced apoptosis (Fig. 1B and C). This observation was confirmed by Nicoletti staining (Fig. 1D), indicating that over a period of 4 h FICZ is being metabolized.

2.2. AHR activation decreases the UVA-photosensitizing effect of FICZ

Given that FICZ is monohydroxylated by CYP1A1, we next stimulated keratinocytes with the AHR agonist tapinarof [27] to induce CYP1A1 expression and enzyme activity and analyze its impact on
FICZ/UVA-induced caspase-3 activity. Treatment of keratinocytes with 100 nM tapinarof for 24 h induced the deethylation of 7-ethoxyresorufin (Fig. 2A), a reaction that is catalyzed by CYP1A isoforms. As human keratinocytes do not express CYP1A2 [28,29], the observed formation of resorufin was specifically catalyzed by CYP1A1. Hence, a pretreatment of keratinocytes with tapinarof should accelerate FICZ clearance and reduce FICZ/UVA-triggered apoptosis in an AHR-dependent manner. AHR-proficient and AHR-knockdown HaCaT keratinocytes were treated for 24 h with 1 μM tapinarof or solvent. Next, cells were treated for 1 h with 100 nM FICZ and subsequently exposed to 5 J/cm² UVA radiation. Exposure to tapinarof, FICZ and UVA radiation alone did not affect caspase-3 activity (Fig. 2B and C). We observed a strong induction of caspase-3 activity in AHR-proficient (HaCaT-EV) and AHR-knockdown (HaCaT-shAHR) cells that were pretreated with DMSO and subsequently exposed to FICZ and UVA radiation. As expected, the FICZ/UVA-triggered induction of caspase-3 activity was nearly completely absent in tapinarof-treated AHR-proficient HaCaT cells but not in the HaCaT-shAHR keratinocytes (Fig. 2B and C), providing evidence that the photosensitizing property of FICZ can be manipulated by activating AHR. The same experimental setup was used to confirm this result in NHEKs. However, upon treatment of the tapinarof- and solvent-preexposed cells for 1 h with FICZ prior to UVA irradiation, we noted no significant difference in the FICZ/UVA-induced caspase-3 activity (Fig. 2D). After elongating the incubation with FICZ for another hour, the FICZ/UVA-dependent caspase-3 activity decreased (Fig. 2E), suggesting that FICZ metabolism in NHEKs occurred slower.

2.3. AHR inhibition enhances FICZ/UVA-induced apoptosis and oxidative stress

To confirm a critical role of AHR in modulating the FICZ/UVA-induced apoptotic response, HaCaT-EV and HaCaT-shAHR keratinocytes were pretreated for 1, 2 and 4 h with 100 nM FICZ and subsequently exposed to 5 J/cm² UVA radiation. Notably, FICZ treatment alone did not induce any detectable caspase-3 activity (Supplementary Fig. S1). Compared to the solvent controls, a FICZ pretreatment for 1 h resulted in an increase of the FICZ/UVA-induced apoptosis in both cell-lines (Fig. 3A and B). An elongation of the FICZ preincubation resulted in
Redox Biology 46 (2021) 102110

4

a decline of FICZ/UVA-triggered apoptosis in HaCaT-EV but not in HaCaT-shAHR keratinocytes (Fig. 3A and B). These results confirmed that by activating AHR FICZ initiated its own CYP1A1-mediated metabolism. As expected, FICZ treatment resulted in an induction of CYP1A1-mediated EROD activity in AHR-proficient but not in AHR-knockdown HaCaT keratinocytes (Fig. 3C). Accordingly, we observed a faster metabolic clearance of exogenously added FICZ in HaCaT-EV compared to HaCaT-shAHR cells (Fig. 3D). After 4 h, ~60% of the applied FICZ was metabolized in HaCaT-EV cells, whereas the FICZ level in HaCaT-shAHR cells declined only for ~25%. When the two cell-lines were treated with 100 nM FICZ for 4 h and subsequently irradiated with 5 J/cm² UVA, we observed a formation of superoxide, which was paralleled by a transcriptional upregulation of heme oxygenase-1 (HOX-1), an established marker for oxidative stress [30], in the HaCaT-shAHR cells (Fig. 3E and F). However, a lower induction of HOX-1 was also observed in the HaCaT-EV cells. These results provided evidence that a modulation of the AHR-CYP1A1 axis directly affects the metabolism of the UVA-photosensitizer FICZ.

2.4. Vemurafenib attenuates FICZ metabolism by interfering with CYP1A1 enzyme activity

As previously reported, vemurafenib is capable of antagonizing the canonical AHR signaling pathway [31,32], indicating that the phototoxic properties of the BRAF inhibitor (BRAFi) may be related to an interference with the CYP1A1-mediated clearance of FICZ. Therefore, we next assessed whether vemurafenib treatment disturbs CYP1A1 enzyme activity and associated FICZ metabolism. HaCaT cells and NHEKs were treated for 24 h with 100 nM FICZ alone and in combination with vemurafenib, the AHR antagonist 3′-methoxy-4'-nitroflavone (MNF) [33] or the CYP1A isoform inhibitor 7-hydroxyflavone (7-HF) [34]. FICZ treatment increased CYP1A enzyme activity, an effect which...
was attenuated by all inhibitors tested (Fig. 4A and B). To investigate whether vemurafenib inhibits CYP1A1 activity directly or indirectly, i.e. by antagonizing AHR and downstream CYP1A1 expression, we pretreated the keratinocytes for 23.5 h with FICZ and subsequently co-exposed the cells to the different inhibitors for just 30 min before the EROD measurement. Importantly, FICZ-induced EROD activity was still reduced in the samples co-treated for 30 min with the BRAFi (Fig. 4C and D), strongly indicating that vemurafenib is a CYP1A1 inhibitor. Noteworthy, in concentrations roughly mirroring or even exceeding plasma levels in patients [35,36], neither dabrafenib nor encorafenib, two additional BRAFi approved for the treatment of advanced melanoma, had an impact on FICZ-induced EROD activity (Supplementary Figs. S2A and B). A co-treatment with vemurafenib reduced the time-dependent metabolic clearance of FICZ in HaCaT keratinocytes (Fig. 4E), supporting our hypothesis that the interference of the BRAFi with CYP1A1 activity is of pathophysiological relevance.

To clarify whether vemurafenib is a substrate of CYP1A1, we investigated the vemurafenib metabolism in more detail using 22 human recombinant CYP isoforms overexpressed in insect cells. Already after 10 min of incubation with 0.5 μM vemurafenib and 10 pmol/ml of the respective enzymes, we observed a considerable depletion of the drug to ~6% of the control level in microsomes expressing CYP1A1 (Fig. 4F). The CYP phenotyping further indicated a minor involvement of CYP1B1, CYP2J2 and CYP3A4. Hence, we next determined the intrinsic clearance (CL_{INT}) rate for vemurafenib of these four CYP isoforms. These analyses confirmed a major role of CYP1A1 for the metabolic clearance of vemurafenib. Already 3 min after incubation, more than 90% of the drug were metabolized by CYP1A1. According to the U.S. Food and Drug Administration (FDA), vemurafenib is a substrate of CYP3A4 [9]. Hence, we were surprised to see that with a CL_{INT} of 83.6 μl/min/pmol CYP1A1 was 76-times more efficient in metabolizing vemurafenib than CYP3A4 (CL_{INT} = 1.1 μl/min/pmol) (Fig. 4G). In addition, we found that CYP2J2 (CL_{INT} = 1.5 μl/min/pmol) was capable to metabolize vemurafenib as efficient as CYP3A4. In contrast to the CYP phenotyping (Fig. 4F), we could not confirm a noteworthy contribution of CYP1B1 (CL_{INT} = 0.5 μl/min/pmol) (Fig. 4G). According to our experience, such variations may occur, in particular when analyzing compounds which are spuriously soluble in aqueous systems. The rapid metabolic breakdown of vemurafenib by CYP1A1 was paralleled by the formation of a monohydroxylated and a dihydroxylated metabolite (Fig. 4H). The dihydroxylated vemurafenib metabolite was generated specifically by CYP1A1 but not by CYP2J2 and CYP3A4 (data not shown). Taken together, these data strongly indicate that vemurafenib is an excellent CYP1A1 substrate at low concentrations and on the other hand a CYP1A1 inhibitor at higher concentrations. Hence, vemurafenib probably interferes with the oxidative metabolism of FICZ.

2.5. Vemurafenib enhances FICZ/UVA-induced apoptosis

To assess whether vemurafenib enhances FICZ/UVA-induced apoptosis, keratinocytes were pretreated with 100 nM FICZ for 2 h and 4 h, respectively. Subsequently, cells were exposed to 0 and 5 J/cm² UVA radiation and immediately treated for 4 h with vemurafenib, 7-HF or solvent. The measurement of caspase-3 activity revealed an increase in the samples treated with FICZ/UVA and vemurafenib (Fig. 5A and B), which was accompanied by a transcriptional induction of the oxidative stress marker HOX-1 (Fig. 5C). Similar results were observed in cells treated with the CYP1A inhibitor 7-HF (Fig. 5D-F), but not in cells treated with the other BRAFi dabrafenib and encorafenib (Supplementary Figs. S2C-E). These results provide evidence that vemurafenib interferes with the metabolic clearance of FICZ and thereby elevates keratinocyte apoptosis in response to UVA irradiation.

2.6. Vemurafenib inhibits UVB-induced apoptosis and CPD removal independently from phototoxicty

The proapoptotic effect of vemurafenib in FICZ/UVA-exposed keratinocytes is to some extent contradictory to the previously reported anti-apoptotic properties of the BRAFi in UVB-irradiated keratinocytes and cutaneous squamous cell carcinoma (SCC) cells [37]. Thus, we next investigated whether vemurafenib also affects UVB-induced apoptosis in our keratinocyte cultures. Irradiation of HaCaT keratinocytes with 200 J/m² UVB enhanced caspase-3 activity, whereas an exposure to a low dose of UVA (5 J/cm²) had no effect on apoptosis (Fig. 6A). A 4 h pretreatment with 40 μM vemurafenib did neither affect the UVB-induced caspase-3 activity nor sensitized the cells to UVB-induced apoptosis (Fig. 6A). However, when HaCaT keratinocytes were pretreated for 4 h with vemurafenib, UVB-irradiated through PBS and subsequently exposed to vemurafenib for another 16 h, a pronounced decline in caspase-3 activity was observed (Fig. 6B). Surprisingly, we observed the same decrease in UVB-induced caspase-3 activity in cells that were only treated with vemurafenib post UVB exposure (Fig. 6C), indicating that this anti-apoptotic effect occurred independently from photochemistry. This result was confirmed in NHEKs treated with vemurafenib immediately after UVB exposure (Fig. 6D). Further analyses of the subG₁ fraction confirmed a dose-dependent anti-apoptotic effect of vemurafenib when added to UVB-irradiated HaCaT cells and NHEKs (Fig. 6E and F). In melanoma patients, vemurafenib treatment stimulates the EGFR receptor (EGFR) [38], which is known to inhibit keratinocyte apoptosis [39]. In fact, a co-exposure of UVB-irradiated HaCaT keratinocytes with the EGFR inhibitor PD153035 reversed the anti-apoptotic effect of vemurafenib (Fig. 6G), suggesting an involvement of the receptor tyrosine kinase. A major driver of UVB-induced apoptosis are DNA double-strand breaks (DSBs) [40]. Comet assay analyses revealed that a treatment of UVB-irradiated HaCaT keratinocytes with vemurafenib significantly reduced DSB formation (Fig. 6H). Given that UVB-induced DSBs mainly result from collapsing replication forks in dividing CPD-positive keratinocytes [41,42] and vemurafenib reversibly inhibits keratinocyte proliferation (Supplementary Figs. S3A and B), we next investigated the impact of vemurafenib on CPD content. Indeed, treatment of HaCaT keratinocytes and NHEKs with vemurafenib immediately after exposure to 200 J/m² UVB resulted in an accumulation of CPDs compared to solvent controls (Fig. 6H and I). These data indicate that vemurafenib, when applied to keratinocytes directly after UVB irradiation, inhibits the proliferation-related formation of DSBs and the associated apoptotic clearance of CPD-positive cells.

3. Discussion

Sensitization of keratinocytes to UVA radiation by the endogenous tryptophan photoproduct FICZ results in the generation of oxidative stress and associated macromolecular damage, which may disrupt skin homeostasis and contribute to extrinsic aging and carcinogenesis [24, 26]. Here, we demonstrate that a manipulation of the AHR-CYP1A1 axis in human keratinocytes has a direct effect on the UVA phototoxicity of FICZ and associated apoptosis, a process that might be relevant for drug-induced cutaneous adverse effects. Specifically, we found that an activation of AHR signaling and the associated induction of CYP1A1 activity results in a rapid clearance of FICZ, whereas an inhibition of this axis leads to an accumulation of FICZ and an enhanced susceptibility to UVA-induced apoptosis.

Although FICZ was identified by mass spectrometry in human skin [43], the concentration range of cutaneous FICZ levels is quite enigmatic. However, as UVB irradiation of human volunteers induces the expression of AHR target genes in the skin [44,45] and sulfated FICZ metabolites are present in human urine [21], it is likely that FICZ is formed in sufficient amounts to activate AHR signaling in vivo. Moreover, UVB radiation-independent sources exist, such as skin-colonizing yeasts, which may elevate cutaneous FICZ level [46,47]. We assume
Fig. 4. Vemurafenib attenuates FICZ metabolism by interfering with CYP1A1 enzyme activity.

(a-d) Identification of CYP1A1 enzyme activity in HaCaT cells and NHEKs treated with different substances (10 μM MNF, 10 μM 7-HF, 25 μM (NHEKs) or 40 μM (HaCaT) Vemurafenib). HaCaT cells (A) (n = 3) and NHEKs (C) (n = 3) were co-exposed for 24 h with one of the three different compounds and 100 nM FICZ. HaCaT cells (B) (n = 3) and NHEKs (D) (n = 3) were treated for 24 h with 100 nM FICZ and MNF, 7-HF or vemurafenib was added 30 min prior to EROD measurement. For statistical analysis a 1-way ANOVA (post-hoc: Tukey test) was performed for all experiments and data are represented as mean ± SEM. (*, p < 0.05 relative to DMSO; #, p < 0.05 relative to DMSO FICZ treatment).

(E) FICZ concentration in the culture medium of HaCaT cells was determined by HPLC analysis. Cells were treated for 4 h with 10 μM MNF, 10 μM 7-HF, 40 μM vemurafenib or solvent and subsequently 100 nM FICZ was added for the indicated time (n = 2).

(F-H) CYP phenotyping for vemurafenib was conducted using 22 recombinant human CYP isoforms overexpressed in insect cells. (F) Microsomal preparations of each CYP isoform (10 pmol/ml) were incubated for 10 min with 0.5 μM vemurafenib. Subsequently, vemurafenib was analyzed by LC/MS (n = 3). For statistical analysis a 1-way ANOVA (un-corrected Fisher’s LSD test) was performed and data are represented as mean ± SEM. (*, p < 0.05 relative to control).

(G) 10 pmol/ml CYP1A1, CYP1B1, CYP2J2 and CYP3A4 were incubated up to 45 min with 0.5 μM vemurafenib in order to determine the intrinsic clearance (CL\text{INT}) (n = 3). For statistical analysis a 1-way ANOVA (post-hoc: Tukey test) was performed and data are represented as mean ± SEM. (*, p < 0.05 for 15, 30 and 45 min relative to 0 min; #, p < 0.05 for 1.5 and 3 min relative to 0 min).

(H) Identification and formation of CYP1A1-derived monohydroxylated and a dihydroxylated vemurafenib (n = 3).
that in healthy skin FICZ levels are rather low and even upon transient inhibition of the AHR-CYP1A1 axis may not reach UVA-reactive concentrations. In contrast, a longer-lasting inhibition of CYP1A1 expression or activity may result in an accumulation of pathophysiologically relevant amounts of FICZ. This might be also true for other tryptophan photoproducts with comparable properties. For example, it is well-known that a UVB irradiation of tryptophan leads to the formation of \(N\)-formylkynurenine \([48-50]\), which is a micromolar photosensitizer for UVA radiation \([49]\) and a precursor for low-affinity AHR ligands, such as kynurenine and kynurenic acid \([51]\). However, to the best of our knowledge, \(N\)-formylkynurenine is not a substrate of CYP1 isoforms.

We have previously reported that vemurafenib binds to AHR and inhibits downstream CYP1A1 gene expression \([31]\). Here we demonstrate that vemurafenib is a substrate for CYP1A1 and interferes with the metabolic degradation of FICZ via inhibition. The resulting accumulation of the potent UVA photosensitizer may contribute to the clinically well-documented and frequently occurring phototoxic side effects of a vemurafenib therapy \([11,12]\). Importantly, exposure of vemurafenib to UVA and UVB radiation in vitro does not lead to ROS formation \([52]\), implying that vemurafenib interacts with cellular molecules and structures to unleash its UVA-photosensitizing properties. Given that cancer patients are treated for several months with vemurafenib, it is tempting to speculate that the cutaneous FICZ level reach UVA-photosensitizing concentrations. Whether at a certain point the accumulating FICZ level might be high enough to override the vemurafenib-mediated inhibition of the canonical AHR pathways and to induce CYP1A1 expression is not known. It is tempting to speculate, whether a topical treatment of the affected skin areas with non-toxic high-affinity AHR ligands may help to reestablish CYP1A1 expression and enforce FICZ clearance. An obvious candidate drug is the bacteria-derived AHR agonist tapinarof which has successfully passed clinical testing for the treatment of psoriasis and atopic dermatitis \([53,54]\).

According to the Zelboraf® approval summary of the FDA \([9]\), vemurafenib is primarily metabolized by CYP3A4. This stands in stark contrast to the results of our in vitro metabolism studies, identifying CYP1A1 as being ~76-times more efficient in clearing vemurafenib than CYP3A4. This discrepancy might be due to the fact that the majority of metabolism studies conducted by the pharmaceutical industry encompass CYP1A2, but not CYP1A1. The same might be true for CYP2J2, which exhibits a comparable intrinsic clearance rate for vemurafenib as CYP3A4. Along the same line, neither CYP1A1 nor CYP2J2 are part of the CYP panel recommended by the guidance documents for the assessment of drug interactions from the FDA \([55]\) and the European Medicines Agency \([56]\). Interestingly, a co-application of the CYP3A4 inhibitor itraconazole had only moderate effects on the steady state level of vemurafenib in patients \([57]\), and both the expression of hepatic CYP1A1 and the pharmacokinetics of vemurafenib exhibit a remarkable interindividual variability \([58,59]\). However, in combination with our previous findings \([31]\), our current data imply that by interfering with AHR and CYP1A1, vemurafenib does not only enforce its own accumulation, but also interferes with the metabolism of other CYP1A1 substrates, in particular co-applied drugs. In fact, CYP1A1 is involved in the metabolism of various clinical drugs, including the antiemetic granisetron \([58]\), the antihypertensive drug riociguat \([58]\), and the anticancer drugs dacarbazine \([60]\), erlotinib \([61]\) and imiquimod \([28]\).
A detrimental consequence of the UVA photosensitization by vemurafenib is the oxidative stress-related disturbance of nucleotide excision repair [62, 63]. Our data, however, clearly show that vemurafenib inhibits the apoptotic clearance of CPD-positive keratinocytes independently from phototoxic stress. Given that UVB-induced keratinocyte apoptosis is mainly triggered by DNA double-strand breaks, which occur when CPD-positive cells start to replicate their genetic material, an inhibition of cell proliferation might be causative for the observed anti-apoptotic effects. The vemurafenib-mediated inhibition of proliferation was reversible by washing out the drug which may resemble declining drug levels in patients. However, in concert with the accumulated CPDs, this process may not only cause an elevated apoptotic response but also increase the risk for mutagenesis and, possibly, skin carcinogenesis. In fact, the development of SCC is a common adverse side effect of vemurafenib monotherapy that occurs in 19%–26% of the treated patients [11]. Unlike UV-induced photocarcinogenesis, vemurafenib therapy-associated SCCs develop rapidly, within the first three months of treatment, and do not only occur in highly sun-exposed but also in low sun-exposed areas of the skin [11, 64]. The pathogenesis of these SCCs may involve a stimulation of

Fig. 6. Vemurafenib affects apoptosis and CPD removal independently from phototoxicity.

(A) Caspase-3 activity was determined in HaCaT cells pretreated for 4 h with 40 μM vemurafenib and irradiated with either 200 J/m² UVB (n = 4), 5 J/cm² UVA (n = 3) or sham (n = 7). 16 h later caspase-3 activity was measured. (B) HaCaT keratinocytes were pretreated with 40 μM vemurafenib for 4 h, were irradiated with 200 J/m² UVB (n = 3), 5 J/cm² UVA (n = 3) or sham (n = 6) and post treated with solvent control or vemurafenib (40 μM) before cells were lysed for caspase-3 activity assay. (C, D) Caspase-3 activity measurement in HaCaT keratinocytes (n = 4) and NHEKs (n = 7) irradiated with 200 J/m² UVB, 5 J/cm² UVA or sham, prior to a 16 h treatment with the indicated vemurafenib concentrations. (E, F) Percentage of apoptotic HaCaT keratinocytes (n ≥ 4) and NHEKs (n = 3) exposed to 200 J/m² UVB radiation or sham and a posttreatment of different vemurafenib concentrations for 24 h. (G) Rate of apoptosis was determined in HaCaT keratinocytes unirradiated or irradiated with 200 J/m² UVB and subsequently treated with vemurafenib for 24 h. In addition, a combined treatment with vemurafenib and PD153035 was conducted for 24 h after UVB radiation or sham treatment (n = 4). (H) DNA-double strand breaks were analyzed in HaCaT cells that were unirradiated or exposed to UVB radiation prior to a treatment with DMSO or vemurafenib for 16 h (n = 3). (I, J) CPD-content was identified in HaCaT keratinocytes (n = 4) and NHEKs (n = 7) irradiated with UVB or sham and post treated with DMSO or the indicated vemurafenib concentrations. For statistical analysis a 2-way ANOVA (post hoc: Tukey test) was performed for all experiments and data are represented as mean ± SEM. (*, p < 0.05 relative to DMSO sham).
mitogenic MEK/ERK signal transduction in BRAF wild-type keratinocytes which probably promotes the proliferation of latent keratinocytes present in the epidermis [11]. A co-treatment with a MEK inhibitor (i.e. the current clinical routine for treating advanced melanoma) does not completely abrogate the development of vemurafenib-associated SCC [11,65], supporting the idea that additional pathomechanisms exist. Results from in vitro studies on human keratinocytes indicated that the activation of mitogenic MEK/ERK signaling occurred only in response to low doses of vemurafenib, i.e. 2 µM or less [66]. We assume that at higher drug concentrations, vemurafenib may promote tumor development by protecting mutated keratinocytes against apoptosis and enhancing genomic instability. A further elucidation of the mechanisms is particularly relevant for patients with Erdheim-Chester disease, which are still treated with vemurafenib and frequently suffer from secondary skin cancers [10].

We have previously reported that an inhibition of AHR signaling attenuates UVB-induced skin carcinogenesis in mice [67]. Specifically, AHR represses nucleotide excision repair and apoptosis in UVB-irradiated keratinocytes [67,68]. Accordingly, AHR inhibition accelerated the removal of DNA-damaged keratinocytes by enforcing DSB-triggered apoptosis [67]. As we have previously identified vemurafenib as an AHR antagonist [31], the anti-apoptotic effect of the BRAFi observed in UVB-exposed keratinocytes was unexpected and urgently requires further investigation. In accordance with literature [38,69], our data suggest that a stimulation of EGFR may be causative for the anti-apoptotic property of vemurafenib.

A limitation of our study is the applied concentration range of vemurafenib. The median maximum plasma concentration at steady state determined in melanoma patients receiving 960 mg vemurafenib b.i.d. is 56.7 ± 21.8 µg/ml, which corresponds to 115.7 ± 44.5 µM [59]. As mentioned above, the authors noted a high interindividual pharmaco-kinetic variability with vemurafenib plasma concentrations ranging from 13 µg/ml (26.5 µM) to 109.8 µg/ml (224.1 µM) [59]. With more than 99%, vemurafenib exhibits a very high plasma protein binding [9], indicating that the concentrations used in this study exceeded clinically relevant concentrations, i.e. the free fraction. However, it should not be underestimated that also during in vitro testing, considerable amounts of vemurafenib will bind to albumin and other proteins present in FBS-supplemented culture medium or even to cell culture plastics [70]. The HIV-1 protease inhibitor lopinavir, for instance, exhibits a comparably high plasma protein binding of 98.9%. A determination of the free fraction of lopinavir in culture medium supplemented with 10% FBS revealed that 96.1% of the drug was bound to serum proteins [71]. However, the potential clinical relevance of the identified mechanisms for the phototoxicity of vemurafenib is strengthened by the fact that a treatment of keratinocytes with dabrafenib and encorafenib neither affected FICZ-induced CYP1A1 enzyme activity nor enhanced FICZ/UV-induced apoptosis. Importantly, a monotherapy with these BRAFIs is less often (<5%) associated with an elevated UVA photosensitivity than vemurafenib [65].

Taken together, a modulation of the CYP1A1-catalyzed metabolism of the endogenous photosensitizer FICZ might be a relevant molecular mechanism responsible for the UVA phototoxicity of vemurafenib. Moreover, vemurafenib treatment inhibited the apoptotic clearance of UVB-irradiated CPD-positive keratinocytes, a mechanism which might contribute to therapy-associated skin carcinogenesis. As vemurafenib is currently in clinical testing for other BRAF V600-mutant malignancies, for instance in combination with rituximab for the treatment of hairy-cell leukemia [72] and as single agent for the treatment of non-small-cell lung cancer [73], a further elucidation of the identified molecular mechanisms is required.

4. Material and methods

4.1. Cell culture, UV irradiation and treatment

HaCaT keratinocytes were cultured in DMEM (PAN Biotech, Aidenbach, Germany) supplemented with 10% fetal bovine serum (PAN Biotech) and 1% antibiotics/antimycotics (PAN Biotech). The generation of HaCaT-EV and HaCaT-shAHR keratinocytes has been previously described [16]. The culture medium of HaCaT-EV and HaCaT-shAHR keratinocytes was supplemented with G418 (Carl Roth, Karlsruhe, Germany). Normal human epidermal keratinocytes were obtained from PromoCell (Heidelberg, Germany) and cultured in Keratinocyte Growth Medium 2 (PromoCell). All cells were cultured at 37 °C in a humidified atmosphere containing 5% CO₂. UV exposure of cells was carried out by using the BS-02 irradiation chamber (Opsyte Dr. Gröbel, Enningen Germany) equipped with individually controllable UVA Actinic and UVB bulbs and respective sensors. For both, UV and sham irradiation, cell culture medium was replaced by PBS. For cell treatment, 6-formylindolo(3,2-b)carbazole (Biomol, Hamburg, Germany), tapinarof, dabrafenib, encorafenib (MedChem Express, Monmouth Junction, NJ, USA), 3′-methoxy-4′-nitroflavone (a kind gift from I. Meyer, Symrise AG, Holzminden, Germany), 7-hydroxyflavone (Sigma-Aldrich, Munich, Germany) and vemurafenib (Selleck Chemicals, Houston, TX, USA) were dissolved in dimethyl sulfoxide.

4.2. Caspase-3 activity assay

Caspase-3 activity was determined by using the Caspase-3 Fluorometric assay Kit (PromoCell) according to the manufacturer’s instructions.

4.3. Nicoletti assay

The analysis of DNA content via Nicoletti staining and flow cytometry was carried out as described previously [68].

4.4. 7-Ethoxyresorufin deethylase (EROD) assay

Measurement of EROD activity in living keratinocyte monolayers was carried out as described previously [74].

4.5. HPLC analysis

To determine FICZ concentration in cell culture medium, 600 µl medium were removed and centrifuged for 5 min at 21,000 × g. Subsequently, 500 µl of the supernatant was taken and mixed with 500 µl of acetonitrile before samples were analyzed by Reverse Phase-HPLC (Shimadzu HPLC system interfaced with the LabSolution software). FICZ was injected onto a Kromasil Eternity C18 column (length = 250 mm, internal diameter = 4 mm, particle size = 5 µm) at 45 °C. The aqueous mobile phase consisted of 0.1% formic acid and the organic phase was acetonitrile with 0.1% acid formic. The flow rate was 1 ml/ min. FICZ was eluted by the following discontinuous gradient at a flow rate of 1 ml/min: the initial concentration of 50% in solvent B increase to 80% over 15 min and this was followed by a decrease to 50% over the next minute, and the initial conditions were then maintained for 9 min. The FICZ was monitored by fluorescence emission (at 525 nm) after excitation at 390 nm. The FICZ was quantified by integration of the peak fluorescence area, employing a respective calibration curve.
4.6. Quantitative real-time PCR

Isolation of total RNA, cDNA synthesis and quantitative real-time PCR was carried out as described previously [74]. Oligonucleotides used in this work were: 5′-CCCAAGGGACCCAGGGGTTGAT-3′ and 5′-GGCATGCTTCTGCGGTTGCGCCTTGGGGT-3′ for β-actin, and 5′-GGCA TGAACCTTTGTCGCGT-3′ and 5′-GGATGCGTCTTGGTITGGGG-3′ for HOX-1.

4.7. ROS measurement

ROS production was measured by using the fluorogenic dye MitoSox (Red Mitochondrial Superoxide Indicator, Thermo Fisher Scientific) and a BD FACS Canto II flow cytometer (BD Biosciences, San Jose, CA, USA). Data analysis was performed using the FlowJo software (Tree Star).

4.8. Incubation of insect microsomes with vemurafenib

Microsomal preparations of 22 heterologously expressed human CYP isoforms were incubated with vemurafenib and prepared for subsequent LC-MS analysis as previously described [25].

4.9. LC–MS analysis

Incubations were analyzed using reversed-phase HPLC with gradient elution using 10 mM ammonium formate and acetonitrile containing 0.1% formic acid as solvents. The HPLC was coupled to a high-resolution mass spectrometer Q-Exactive® (Thermo Scientific, Bremen Germany) operated in full-scan mode. Selectivity of the analytes was gained by extracting a very narrow mass range in the order of 10–20 ppm of the exact mass of the analyte.

4.10. Cell viability assay

Cell viability was analyzed by using CellTiter-Blue Cell Viability Assay (Promega, Mannheim, Germany) according to the manufacturer’s instructions.

4.11. Cell proliferation assay

Cell division was analyzed using the CellTrace Cell Proliferation Kit (Invitrogen, Carlsbad, CA, USA) and a FACS Canto II Flow Cytometer (BD, Franklin Lakes, NJ, USA).

4.12. Comet assay

The analysis of DNA double-strand breaks via Comet assay was carried out as described previously [67].

4.13. Southwestern slot–blot analysis

Isolation of DNA and Southwestern slot–blot-based quantification of CPDs was isolated as described previously [67]. The anti-CPD monoclonal antibody (clone TDM-2) was purchased from Cosmo Bio (Carlsbad, CA, USA).

4.14. Statistical analysis

All experiments were performed independently at least three times unless otherwise noted. Data are presented as mean ± standard error of the mean (SEM). Statistical analyses were performed using Graph Pad Prism 8.4.2 (GraphPad Prism Software, California, USA). A one-factor analysis of variance (ANOVA) was performed to compare means of more than two samples. In the case of multiple factor dependence, a two-factor ANOVA was performed. A value of p ≤ 0.05 was considered statistically significant.

Declaration of competing interest

The authors declare no competing financial interests.

Acknowledgment

We thank Petra Boukamp and Ellen Frische for providing cell-lines and Imke Meyer for generously donating MNF. We thank Volker Lambertz and Frederick Hartung for technical support. VG was supported by the EU program Erasmus+. This work was supported by grants of the Jürgen Manchot Foundation (to KMR and NCS).

Appendix A. Supplementary data

Supplementary data to this article can be found online at https://doi.org/10.1016/j.redox.2021.102110.

References

[1] A.R. Young, J. Claveau, A.B. Rossi, Ultraviolet radiation and the skin: photobiology and sunscreen photoprotection, J. Am. Acad. Dermatol. 76 (3S1) (2017) S100–S109.
[2] J.J. Bernard, R.L. Gallo, J. Krutmann, Photoimmunology: how ultraviolet radiation affects the immune system, Nat. Rev. Immunol. 19 (11) (2019) 688–701.
[3] J. Krutmann, A. Morita, J.H. Chung, Sun exposure: what molecular photodermatologist tells us about its good and bad sides, J. Invest. Dermatol. 132 (3 Pt 2) (2012) 976–984.
[4] J. Cadet, T. Douki, Formation of UV-induced DNA damage contributing to skin cancer development, Photochem. Photobiol. Sci. 17 (12) (2018) 1816–1841.
[5] G.T. Wróndrak, M.K. Jacobson, E.L. Jacobson, Endogenous UVA-photosensitizers: mediators of skin photodamage and novel targets for skin photoprotection, Photochem. Photobiol. Sci. 5 (2) (2006) 215–237.
[6] K.M. Blakely, A.M. Drucker, C.F. Rosen, Drug-induced photosensitivity-an update: culprit drugs, prevention and management, Drug Saf. 42 (7) (2019) 827–847.
[7] S. Lembo, A. Raimondo, V. Conti, M. Venturini, Photosensitivity and cancer immune-targeted therapies, Photodermatol. Photoimmunol. Photomed. 36 (3) (2020) 172–178.
[8] K.P. Flaherty, I. Puzanov, K.B. Kim, A. Ribas, G.A. McArthur, J.A. Sosman, P. J. D’Oreyer, R.J. Lee, J.F. Grippol, K. Nolop, P.B. Chapman, Inhibition of mutated, activated BRAF in metastatic melanoma, N. Engl. J. Med. 363 (9) (2010) 809–819.
[9] G. Kim, A.E. McKee, Y.M. Nings, M. Hazarika, M. Theoret, J.R. Johnson, Q.C. Xu, S. Tang, R. Sridhara, X. Jiang, K. He, D. Roscoe, W.D. Mcguinn, W.S. Helms, A. M. Russell, S.P. Mikiński, J.F. Zirkelbach, J. Earp, Q. Liu, A. Ibrahim, R. Justice, R. Pazdur, FDA approval summary: vemurafenib for treatment of unresectable or metastatic melanoma with the BRAFV600E mutation, Clin. Canc. Res. 20 (19) (2014) 4994–5000.
[10] P.A. Oneal, V. Kwitkowski, L. Luo, Y.L. Shen, S. Subramaniam, S. Shord, K. B. Goldberg, A.E. McKee, E. Kaminiski, A. Farrell, R. Pazdur, FDA approval summary: vemurafenib for the treatment of patients with erdheim-chester disease with the BRAFV600E mutation, Oncol. 23 (12) (2018) 1520–1524.
[11] M.E. Lacouture, M. Duvie, A. Hauschild, V.G. Prieto, C. Robert, D. Schadendorf, C. C. Kim, C.J. McCormack, P.L. Mykowsk, O. Spleiss, K. Trunzer, F. Sa, S. Nelson, K.B. Nolop, J.F. Grippol, R.J. Lee, M.J. Klimek, J.J. Troy, A.K. Joe, Analysis of dermatologic events in vemurafenib-treated patients with melanoma, Oncol. 18 (3) (2013) 314–322.
[12] R. Dammer, J. Rinderknecht, S.M. Goldanger, Ultraviolet A and photosensitivity during vemurafenib therapy, N. Engl. J. Med. 366 (5) (2012) 480–481.
[13] A. Rannug, J. Grafstrom, K. Grafstrom, Certain photooxidized derivatives of tryptophan bind with very high affinity to the Ah receptor and are likely to be endogenous signal substances, J. Biol. Chem. 262 (32) (1987) 15422–15427.
[14] W.G. Helferich, M.S. Denison, Ultraviolet photoproducts of tryptophan can act as dioxin agonists, Mol. Pharmacol. 40 (5) (1991) 674–678.
[15] R. Dummer, A. Rannug, U. Sjoberg, J. Grafstrom, Certain photooxidized derivatives of tryptophan bind with very high affinity to the Ah receptor and are likely to be endogenous signal substances, J. Biol. Chem. 262 (32) (1987) 15422–15427.
[16] W.G. Helferich, M.S. Denison, Ultraviolet photoprodut of tryptophan can act as dioxin agonists, Mol. Pharmacol. 40 (5) (1991) 674–678.
[17] A. Rannug, R. Dummer, J. Grafstrom, Certain photooxidized derivatives of tryptophan bind with very high affinity to the Ah receptor and are likely to be endogenous signal substances, J. Biol. Chem. 262 (32) (1987) 15422–15427.
[18] G. Kim, A.E. McKee, Y.M. Ning, M. Hazarika, M. Theoret, J.R. Johnson, Q.C. Xu, S. Tang, R. Sridhara, X. Jiang, K. He, D. Roscoe, W.D. Mcguinn, W.S. Helms, A. M. Russell, S.P. Mikiński, J.F. Zirkelbach, J. Earp, Q. Liu, A. Ibrahim, R. Justice, R. Pazdur, FDA approval summary: vemurafenib for treatment of unresectable or metastatic melanoma with the BRAFV600E mutation, Clin. Canc. Res. 20 (19) (2014) 4994–5000.
[19] V. Rothhammer, F.J. Quintana, The aryl hydrocarbon receptor: an environmental hydrocarbon receptor as a target of environmental stressors – implications for adaptive metabolism, ligand diversity, and the xenokine model, Chem. Res. Toxicol. 33 (4) (2020) 860–879.

K.M. Rolfes et al. Redox Biology 46 (2021) 102110
K.M. Rolfe et al.  Redox Biology 46 (2021) 102110
R. Anforth, A. Menzies, K. Byth, G. Carlos, S. Chou, R. Sharma, R.A. Scolyer, R. Kefford, G.V. Long, P. Fernandez-Penas, Factors influencing the development of cutaneous squamous cell carcinoma in patients on BRAF inhibitor therapy, J. Am. Acad. Dermatol. 72 (5) (2015) 809–815 e1.

A. Daud, K. Tsai, Management of treatment-related adverse events with agents targeting the MAPK pathway in patients with metastatic melanoma, Oncol. 22 (7) (2017) 823–835.

M.R. Roh, J.M. Kim, S.H. Lee, H.S. Jang, K.H. Park, K.Y. Chung, S.Y. Rha, Low-concentration vemurafenib induces the proliferation and invasion of human HaCaT keratinocytes through mitogen-activated protein kinase pathway activation, J. Dermatol. 42 (9) (2015) 881–888.

M. Pollet, S. Shaik, M. Mescher, K. Frauenstein, J. Tigges, S.A. Braun, K. Sondenheimer, M. Kaveh, A. Bruhs, S. Meller, A. Schwarz, C. Esser, T. Douki, C.F.A. Vogel, J. Krutmann, T. Haarmann-Stemmann, The AhR represses nucleotide excision repair and apoptosis and contributes to UV-induced skin carcinogenesis, Cell Death Differ. 25 (10) (2018) 1823–1836.

K. Frauenstein, U. Sydlik, J. Tigges, M. Majora, C. Wiek, H. Hanenberg, J. Abel, C. Esser, E. Fritsche, J. Krutmann, T. Haarmann-Stemmann, Evidence for a novel anti-apoptotic pathway in human keratinocytes involving the aryl hydrocarbon receptor, E2F1, and checkpoint kinase 1, Cell Death Differ. 20 (10) (2013) 1425–1434.

A. Gross, A. Niemetz-Rahn, A. Nonnenmacher, J. Tucholski, U. Keilholz, A. Furi, Expression and activity of EGFR in human cutaneous melanoma cell lines and influence of vemurafenib on the EGFR pathway, Targeted Oncol. 10 (1) (2015) 77–84.

J. Kruttm, H. Höltert, C. Fisher, M. Leist, Chemical concentrations in cell culture compartments (C5) - free concentrations, ALTEX 37 (4) (2020) 693–708.

D. Hickman, S. Vasavanonda, G. Nequist, L. Colletti, W.M. Kati, R. Bertz, A. Hsu, D. J. Kempf, Estimation of serum-free 50-percent inhibitory concentrations for human immunodeficiency virus protease inhibitors lopinavir and ritonavir, Antimicrob. Agents Chemother. 48 (8) (2004) 2911–2917.

E. Tiacci, L. De Carolis, E. Simonetti, M. Capponi, A. Ambrosetti, E. Lucia, A. Antolino, A. Paloni, S. Ferrari, P.L. Zinzani, S. Ascani, V.M. Perriello, L. Rigacci, G. Gaidano, R. Della Setta, N. Frattarelli, P. Falcucci, P. Pio, G. Vissani, F. Zaja, B. Falini, Vemurafenib plus rituximab in refractory or relapsed hairy-cell leukemia, N. Engl. J. Med. 384 (19) (2021) 1810–1823.

J. Mazieres, C. Crozet, L. Montane, F. Barlesi, F. Barlesi, P.J. Souquet, X. Quantin, C. Dubos-Arvis, J. Otto, L. Favier, V. Avrilhon, J. Cadran, D. Moro-Sibilot, I. Monnet, V. Westeel, J. Le Treut, E. Brain, J. Tredaniel, M. Jaffro, S. Collot, G.R. Ferretti, C. Tiffon, C. Mahier-Ait Oukhatar, J.Y. Blay, Vemurafenib in non-small-cell lung cancer patients with BRAF(V600) and BRAF(nonV600) mutations, Ann. Oncol. 31 (2) (2020) 289–294.

K. Frauenstein, J. Tigges, A.A. Sosilov, S. Kado, N. Raab, E. Fritsche, J. Haendeler, M.S. Denison, C.F. Vogel, T. Haarmann-Stemmann, Activation of the aryl hydrocarbon receptor by the widely used Src family kinase inhibitor 4-amino-5-(4-chlorophenyl)-7-(dimethylethyl)pyrazolo[3,4-d]pyrimidine (PP2), Arch. Toxicol. 89 (8) (2015) 1329–1336.